product name Spironolactone
Description: Spironolactone is a potent antagonist of the androgen receptor with IC50 of 77 nM. Spironolactone is a drug mainly used for the treatment of fluid build-up caused by heart failure, liver scarring, or kidney disease. It can also be used to treat high blood pressure, low blood potassium that does not improve with supplementation, early puberty, excessive hair growth in women, and as a component of hormone replacement therapy for trans women.
References: J Biol Chem. 2010 Sep 24;285(39):29932-40; Mol Cell Endocrinol. 1974 Dec;2(1):59-67.
416.57
Formula
C24H32O4S
CAS No.
52-01-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 83 mg/mL (199.2 mM)
Water: <1 mg/mL
Ethanol: 20 mg/mL (48.0 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19395034
| In Vitro |
In vitro activity: Spironolactone is a strong AR antagonist (IC50 ~ 77 nM), a weak GR antagonist (IC50 ~ 2.4 μM), and a weak PR agonist (EC50 ~ 740 nM). Spironolactone inhibits androstanolone binding in rat prostate nuclei and androstanolone specific binding in rat prostate cytosol. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Spironolactone (1 mg/day) exerts anti-androgenic activity in rats. A single pretreatment of spironolactone (1 mg/rat) inhibits specific and saturable uptake of hormone into prostate induced by tracer dose administration of [3H]testosterone. |
| Animal model | |
| Formulation & Dosage | |
| References | J Biol Chem. 2010 Sep 24;285(39):29932-40; Mol Cell Endocrinol. 1974 Dec;2(1):59-67. |
Related Posts
product name Spironolactone
Description: Spironolactone is a potent antagonist of the androgen receptor with IC50 of 77 nM. Spironolactone is a drug mainly used for the treatment of fluid build-up caused by heart failure, liver scarring, or kidney disease. It can also be used to treat high blood pressure, low blood potassium that does not improve with supplementation, early puberty, excessive hair growth in women, and as a component of hormone replacement therapy for trans women.
References: J Biol Chem. 2010 Sep 24;285(39):29932-40; Mol Cell Endocrinol. 1974 Dec;2(1):59-67.
416.57
Formula
C24H32O4S
CAS No.
52-01-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 83 mg/mL (199.2 mM)
Water: <1 mg/mL
Ethanol: 20 mg/mL (48.0 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19395034
| In Vitro |
In vitro activity: Spironolactone is a strong AR antagonist (IC50 ~ 77 nM), a weak GR antagonist (IC50 ~ 2.4 μM), and a weak PR agonist (EC50 ~ 740 nM). Spironolactone inhibits androstanolone binding in rat prostate nuclei and androstanolone specific binding in rat prostate cytosol. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Spironolactone (1 mg/day) exerts anti-androgenic activity in rats. A single pretreatment of spironolactone (1 mg/rat) inhibits specific and saturable uptake of hormone into prostate induced by tracer dose administration of [3H]testosterone. |
| Animal model | |
| Formulation & Dosage | |
| References | J Biol Chem. 2010 Sep 24;285(39):29932-40; Mol Cell Endocrinol. 1974 Dec;2(1):59-67. |